SB-3CT alone substantially extended the overall survival time (median survival37 vs 22 days; p < 0.01) of B16F10 tumor-bearing mice, and combined with anti-CTLA-4, enhanced the survival benefit (median survival time: 58 vs 22 days; p < 0.001; Fig. 6c). The gene discussed is CTLA4; the disease is neoplasm.